Parabilis Medicines, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 28.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.50B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Details
| Name | Parabilis Medicines, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 145 |
| Founded | 2015 |
| Ipo Date | 2026-06-10 |
| Ceo | Mathai Mammen |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US6989551014 |
| Cusip | 698955101 |
| Cik | 1657677 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Mathai Mammen M.D., Ph.D. | Chief Executive Officer, President, Treasurer and Chairman |
| Teresa L. Jurgensen J.D. | Executive Vice President, Secretary and General Counsel |
| John McGee Ph.D. | Scientific Co-Founder, Executive Vice President and Head of Platform |
| Thomas Rodolpho Kotarakos | Chief Financial Officer |
| Dr. Rohin Mhatre Ph.D. | Chief Technical Operations Officer |
| Kristen Stants | Chief People Officer |
| Dr. Jonathan Hurov Ph.D. | Executive Vice President of Discovery Biology |
| Marie Nguyen M.D. | Senior Vice President and Head of Clinical Development |
| Dr. Markus Haeberlein MSc, Ph.D. | Executive Vice President of Discovery Science |
| Dr. Huei-in Ho Ph.D. | Chief Business and Strategy Officer |
Contact
| Address | 30 Acorn Park Drive, Cambridge, Massachusetts 02140, United States |
| Phone | (617) 945-9510 |
| Website | https://parabilismed.com |